Incretin-Based Therapy for MASH: Metabolic Target Organ Damage | July 2026

Introduction:

The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing promise in resolving steatohepatitis and slowing fibrosis progression, raising the question of whether dual-target incretin therapies may outperform GLP-1 receptor agonists alone.

Why was this review needed?

With multiple incretin-based agents now available or in development, clinicians need to understand whether dual agonists offer meaningful advantages over GLP-1 monotherapy and how they compare with other approved therapies such as resmetirom.

What did the review show?

• GLP-1 receptor agonists and dual incretin therapies consistently achieve high rates of MASH resolution.
• Semaglutide significantly improved both steatohepatitis resolution and fibrosis in phase III studies.
• Dual agonists such as tirzepatide, survodutide, and pemvidutide target complementary metabolic pathways and may provide greater reductions in hepatic fat and body weight.
• In the IMPACT phase II trial, pemvidutide achieved MASH resolution in over half of treated patients but did not significantly improve fibrosis after only 24 weeks.
• Improvements in liver fat, liver enzymes, and several non-invasive fibrosis biomarkers were observed with pemvidutide.
• Gastrointestinal adverse events remained the most common side effects and were generally manageable.
• Longer-duration studies are needed to determine whether early metabolic improvements translate into meaningful fibrosis regression.

Clinical Impact:

Incretin-based therapies are becoming a major pillar of MASH treatment. Dual-target agents may provide additional metabolic benefits beyond GLP-1 monotherapy, but their long-term impact on fibrosis, treatment duration, and combination strategies remains to be established.

Take-Home Message:

Incretin therapies are reshaping the treatment of MASH. While dual-target agents appear biologically promising and achieve high rates of steatohepatitis resolution, whether two mechanisms are truly better than one for reversing liver fibrosis will require longer-term phase III evidence.